A novel robotic wastewater analysis system to quantify opioid exposure and treatment in residential communities

项目摘要 该拟议的一期/二期FastTrack SBIR项目将演示 强大的废水测试和分析平台，政府利益相关者可以使用该平台指导 应对阿片类药物流行病的本地化行动。阿片类药物的流行是最大的药物 这是美国历史上最严重的危机，每天造成130多人死亡。目前，利益相关者使用 过量死亡数据来指导他们的阿片类药物反应策略。然而，这一数据并不经常 更新，通常在地理级别上汇总，这些级别太大，公众无法采取行动 卫生官员，很少提供对具体药物类型（如处方药与非法药物）的深入了解 阿片类药物、芬太尼等）。提供本地化、实时和药物特异性的新数据源 在这一迅速变化的流行病中，需要有深入的见解来指导应对工作。 基于水的检测是一种很有前途的方法，用于测量人口水平的药物 风险，但在对利益相关者有用之前， 疫情的前线。具体而言，目前的废水测试方法依赖于采样 在污水处理厂，这产生了城市一级的数据最好的。这表示 而且对指导局部干预没有用处。 Biobot是第一个商业废水测试技术，旨在提供 为应对阿片类药物流行病的市政利益相关者提供可操作的公共卫生见解。我们 机器人废水分析系统测量阿片类药物暴露和处理（区分 人类使用从丢弃在厕所），并在社区一级运作- 与市政利益攸关方相关的地理分辨率。我们平台的首个版本 包括（1）选择代表住宅的采样点（检修孔）的算法， 城市社区;（2）可以安装在下水道下的机器人采样设备 入口（例如井盖），以收集24小时复合样品;（3）HPLC-MS/MS 检测处方阿片类药物，美沙酮， 丁丙诺啡和纳洛酮;和（4）打印报告中的可视化。 此快速通道第一阶段/第二阶段应用程序的目标是改进我们的平台， 在全国各地的城市都可以采用。与布里格姆的顶尖毒理学家合作， 妇女医院和哈佛医学院，我们将解决技术差距，以改善 数据可靠性和从检测到阿片类药物暴露的一致量化， 治疗在第一阶段，我们将改进和扩展我们的HPLC-MS/MS方法，开发 模拟模型，以优化样本收集，并解决变异性的挑战， 24-小时采样。在第二阶段，我们将开发数据校正方法， 与所有现有的下水道基础设施，验证我们的数据对报告的过量在一个试点 研究了马萨诸塞州的六个城市，并建立了一个数据分析和可视化 为我们的终端用户提供平台。 成功完成拟议的项目将导致优化和验证 废水测试技术，提供准确、空间粒度和更实时的 关于阿片类药物暴露和治疗的数据。在技术发展的同时， 将使我们能够向两个主要客户展示我们产品的价值：波士顿市 以及马萨诸塞州的法律。这两个政府组织是关键的支持者， 为我们的目标客户长期采用铺平道路。

Project Summary This proposed Phase I/Phase II FastTrack SBIR project will lead to the demonstration of a robust wastewater testing and analytics platform that government stakeholders can use to guide localized actions to respond to the opioid epidemic. The opioid epidemic is the biggest drug crisis in American history, resulting in over 130 deaths every day. Currently, stakeholders use overdose death data to guide their opioid response strategies. However, this data is infrequently updated, often aggregated at geographic levels which are too large to be actionable by public health officials, and rarely provides insight into specific drug types (e.g. prescription vs. illicit opioids, fentanyl, etc.). Novel data sources which provide localized, real-time, and drug-specific insights are needed to inform response efforts in this rapidly changing epidemic. Wastewater-based testing is a promising approach for measuring population-level drug exposure, but has significant technical limitations before it can be useful to stakeholders on the frontlines of the epidemic. Specifically, current wastewater testing approaches rely on sampling at wastewater treatment plants, which yields city-level data at best. This represents a heterogenous sample and is not useful to guide localized interventions. Biobot is the first commercial wastewater testing technology designed and built to provide actionable public health insights for municipal stakeholders tackling the opioid epidemic. Our robotic wastewater analysis system measures opioid exposure and treatment (distinguishing human use from discarding in the toilet), and operates at the neighborhood-level — the geographic resolution relevant to municipal stakeholders. The premiere version of our platform includes (1) an algorithm to select sampling sites (manholes) that represent residential communities in a municipality; (2) a robotic sampling device that can be installed under sewer access portals (e.g. manhole covers) to collect 24-hour composite samples; (3) a HPLC-MS/MS method that detects a variety of urinary metabolites of prescription opioids, methadone, buprenorphine, and naloxone; and (4) visualization in printed reports. The goal of this Fast Track Phase I/Phase II application is to improve our platform to make it adoptable in cities across the nation. In collaboration with leading toxicologists at Brigham and Women’s Hospital and Harvard Medical School, we will address technological gaps to improve data reliability and move from detection to consistent quantification of opioid exposure and treatment. In Phase I, we will improve and expand our HPLC-MS/MS method, develop simulation models to optimize sample collection, and address the variability challenge of 24-hour sampling. In Phase II, we will develop data correction methods to enable integration with all existing sewer infrastructures, validate our data against reported overdoses in a pilot study across six Massachusetts municipalities, and build a data analytics and visualization platform for our end users. Successful completion of the proposed project will lead to an optimized and validated wastewater testing technology that provides accurate, spatially granular, and more real-time data on opioid exposure and treatment. In parallel with the technological development, this grant will allow us to demonstrate the value of our product to two key customers: the City of Boston and the State of Massachusetts. These two government organizations are key champions to pave the way for long-term adoption by our target customers.